One major limitation of neutralizing antibody-based COVID-19 therapy is the requirement of
costly cocktails to reduce emergence of antibody resistance. Here we engineer two …

The highly mutated and transmissible Omicron (BA. 1) and its more contagious lineage BA.
2 have provoked serious concerns over their decreased sensitivity to the current COVID-19 …

Prevention of viral escape and increased coverage against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal …

Passive immunization using monoclonal antibodies will play a vital role in the fight against
COVID-19. The recent emergence of viral variants with reduced sensitivity to some current …

As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to
threaten public health worldwide, the development of effective interventions is urgently …

The emergence of SARS-CoV-2 antibody escape mutations highlights the urgent need for
broadly neutralizing therapeutics. We previously identified a human monoclonal antibody …

Two and a half years into the COVID-19 pandemic, we have gained many insights into the
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …

The COVID19 pandemic, caused by SARS-CoV-2, has infected more than 200 million
people worldwide. Due to the rapid spreading of SARS-CoV-2 and its impact, it is paramount …

Understanding the properties and mechanisms by which antibodies provide protection is
essential to defining immunity. Although neutralizing antibodies have been proposed as a …

Monoclonal antibodies are an efficacious therapy against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). However, rapid viral mutagenesis led to escape …